













Apoptosis and cellular senescence, two key tumor 
suppression mechanisms, are thought to be 
antagonistically pleiotropic. Antagonistic pleiotropy 
holds that functions that are advantageous for a young 
and reproductively fit organism (eg. cancer protection 
and proper development) can be deleterious when that 
same organism becomes old (eg. loss of stem cell 
proliferation and tissue degeneration leading to diseases 
associated with age) [1]. This theory predicts that in an 
older animal (or human), the activity of tumor 
suppressors would be associated with enhanced aging 
phenotypes. However, confirmation of a direct 
connection between apoptosis, senescence and aging 
remains elusive [2]. In fact, at least in the case of p53 
there is mounting data challenging the antagonistic 
pleiotropy model.  
 
Multiple lines of evidence from animal models suggest 
that a functional p53 pathway favors prolonged 
survival. Aging mice show a decrease in p53 activity 
correlated with increased tumor incidence as well as an 
overall reduction in longevity [3]. On the other hand, 
mice with an extra gene dosage of Arf and p53 show 
significant tumor protection, decreased oxidative 
damage and delayed aging [4]. Animals expressing the 
p53
S18A  mutation present with  accelerated aging, 
and cells from these mice  undergo early  senescence 
[5].  As phosphorylation of p53 at Ser18 (Ser15 in 
humans) is associated with activation, these results 
highlight a requirement for intact p53 signaling in 
longevity [6]. In the nematode
 Caenorhabditis elegans, 
mutations that lead to longevity preferentially 
antagonize tumor growth, likely due to an increase in 
DAF-16/p53–dependent
 apoptosis [7].   
 
The mTOR pathway is intimately connected with 
organismal aging. In fact inhibition of mTOR either by 
treatment with rapamycin or by the inhibition of 
upstream signaling molecules, extends lifespan in yeast, 















one of the main mechanisms that decrease lifespan [8]. 
p53 is able to regulate activity of mTOR following 
DNA damage or oncogenic stress by activation of 
PTEN, AMP kinase and TSC-2, each of which signals 
to diminish the activity of mTOR (Figure 1) [9, 10]. p53 
may also function downstream of mTOR by activating 
antioxidant genes and thus protecting cells against 
increased ROS levels in cells, one of the consequences 
of heightened mTOR activity [11-13].  
 
As the ability of p53 to increase longevity becomes 
more evident, we should consider the role of its 
negative regulator, Mdm2, if not in the process of aging 
directly, at least in its effects on the activity of mTOR. 
Growth factor and oncogene signaling activate PI-3 
kinase and its downstream effector AKT, a protein 
kinase that activates mTOR via inhibition of TSC-1 
protein.  AKT also phosphorylates Mdm2 leading to 
enhanced Mdm2 ubiquitin ligase activity and more 
rapid degradation of p53 (Figure 1) [8, 14]. 
Additionally, AKT stimulates FOXO phosphorylation, 
which results in FOXO nuclear exportation and 
ubiquitin dependent proteasomal degradation [15]. 
FOXO proteins have conserved abilities to increase 
longevity in worms and flies [16]. Indeed, Mdm2 was 
reported to function as an E3 ubiquitin ligase to 
promote FOXO degradation, following activation of 
AKT, thus forging an additional link between Mdm2 
and changes in longevity [17]. 
 
Additionally, mTOR is able to positively regulate 
Mdm2 through an increase in translation of Mdm2 
mRNA. Consistently, an increase in p53 dependent 
apoptosis in the liver of mouse embryos treated with 
Rapamycin  in utero is attributed mTOR’s ability to 
control translation of Mdm2 [18]. However, because the 
interplay between apoptosis and aging is likely to be 
highly context specific, it is important to note that mice 
expressing only ~30% of the wild type Mdm2 levels do 
not have an aging phenotype, while exhibiting clear en- 
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hancement in tumor protection [19].  It would be of 
interest to look at the effects of nutrient deprivation on 
the mice carrying an Mdm2 hypomorphic allele.  
 
In conclusion, as our notion of p53 function in aging 
and senescence changes, it is very tempting to imagine 
that just a slight inhibition of Mdm2 function in cells 
could both prolong full tumor surveillance mechanisms 
of p53, and in some circumstances increase longevity. 
Numerous molecular inhibitors of Mdm2 are in various 
stages of development with the goal of reactivating p53 
activity in cancer [20]. The idea that controlled 
pharmacological modulation of Mdm2 function might 
also have positive consequences in extension of human 
lifespan could be an unexpected benefit and an 
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Conversely,  Mdm2  can  activate  mTORC1  by  targeting  p53  for  degradation.  p53  negatively  regulates
mTORC1 by activating TSC1/2 (tuberous sclerosis 1/2) complex, which acts as a GTPase activating protein
(GAP)  for  Rheb  (Ras  homologue  enriched  in  brain).  p53  can  also  repress  the  activity  of  PI‐3K
(phosphatidylinositol  3‐kinase)  by  induction  of  PTEN  (phosphatase  and  tensin  homologue),  leading  to
further downregulation of mTORC1. Arrows represent up‐regulation. Orange diamonds represent kinase
activity.  Blue  diamonds  represent  E3  ubiquitin  ligase  activity  of  Mdm2.  AMPK,  AMP‐activated  protein
kinase; FOXO, Forkhead box; PDK1, 3‐phosphoinositide‐dependent protein kinase 1. 
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